Eileen Wang, MD
Allergy & Immunology · Denver, CONPI 1710290192
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $195,325 of the $273,989 with a category attached, or 71.3%. AstraZeneca accounts for 71.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $160,915, more than ten times the $1,494 reported in 2019. Among allergy & immunology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $848.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$196K
- GSK$43K
- Amgen$17K
- Genentech USA, Inc.$11K
- Astrazeneca UK Limited$7K
- Abbott$152
- plus $241 from 4 others
Across 50 payments — averaging $39,771 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1.7M
- GSK$156K
- Genentech, Inc.$61K
- Novartis$36K
What the payments were for
- Consulting fees$41,42215%
- Speaking & faculty fees$195,32571%
- Travel & lodging$29,70911%
- Food & beverage$7,5333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 237 | $195,701 |
| GSK | 44 | $42,741 |
| Amgen | 7 | $16,775 |
| Genentech USA, Inc. | 14 | $11,007 |
| Astrazeneca UK Limited | 14 | $7,372 |
| Abbott | 1 | $152 |
| Teva Pharmaceuticals USA, Inc. | 2 | $112 |
| Regeneron Healthcare Solutions, Inc. | 2 | $87 |
| Regeneron | 1 | $26 |
| Optinose US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$273,989 in reported general payments places this provider in the 90th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 72 | $286,154 |
| Dupixent SyringeDupilumab | 41 | $155,411 |
| HyqviaIgg/Hyaluronidase,recombinant | 34 | $139,440 |
| Fasenra PenBenralizumab | 20 | $109,647 |
| TezspireTezepelumab-Ekko | 12 | $49,372 |
| Spiriva RespimatTiotropium Bromide | 28 | $23,390 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $15,614 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $11,702 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $10,861 |
| AlvescoCiclesonide | 12 | $10,305 |
| DuleraMometasone/Formoterol | 13 | $8,348 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,338 |
| AirsupraAlbuterol Sulfate/Budesonide | 12 | $5,441 |
| Budesonide | 18 | $4,747 |
| Arnuity ElliptaFluticasone Furoate | 18 | $4,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort, Airsupra | $195,701 | $70,42757 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $42,741 | $15,39430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Denver
- Rohit KatialDenver$758K
- Donald LeungDenver$208K
- Flavia HoyteDenver$70K
- Bruce LanserDenver$34K
- Shaila GogateDenver$21K
- Harold NelsonDenver$14K
- Anna MeyerDenver$9K
- Monica ReddyDenver$6K
- Jessica HuiDenver$5K
- Ronina CovarDenver$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.